Neuropharmacokinetic visualization of regional and subregional unbound antipsychotic drug transport across the blood–brain barrier

Dominika Luptáková¹, Theodosia Vallianatouº¹, Anna Nilsson¹,², Reza Shariatgorji¹,², Margareta Hammarlund-Udenaes³, Irena Loryan² and Per E. Andrén¹,²

© The Author(s) 2021

Comprehensive determination of the extent of drug transport across the region-specific blood–brain barrier (BBB) is a major challenge in preclinical studies. Multiple approaches are needed to determine the regional free (unbound) drug concentration at which a drug engages with its therapeutic target. We present an approach that merges in vivo and in vitro neuropharmacokinetic investigations with mass spectrometry imaging to quantify and visualize both the extent of unbound drug BBB transport and the post-BBB cerebral distribution of drugs at regional and subregional levels. Direct imaging of the antipsychotic drugs risperidone, clozapine, and olanzapine using this approach enabled differentiation of regional and subregional BBB transport characteristics at 20-µm resolution in small brain regions, which could not be achieved by other means. Our approach allows investigation of heterogeneity in BBB transport and presents new possibilities for molecular psychiatrists by facilitating interpretation of regional target-site exposure results and decision-making.

Molecular Psychiatry (2021) 26:7732–7745; https://doi.org/10.1038/s41380-021-01267-y

INTRODUCTION

The unique role of CNS barriers including the blood–brain (BBB) and blood–cerebrospinal fluid (BCSFB) barriers in regulating neural microenvironments and the transport of xenobiotics has been recognized in multiple studies. A growing body of clinical evidence indicates that CNS barriers are involved in both the pathogenesis and the pathophysiology of several mental disorders including schizophrenia (SZ) [1–3]. The changes associated with SZ are complex and range from very fine ultrastructural changes in neurovascular units to clinically documented functional changes in drug transport across the BBB at the level of entire brain regions [4–7]. Recent studies by researchers in the BBB community have highlighted important unanswered questions pertaining to (a) the potential link between antipsychotic medication and impairment of BBB function, (b) targeting of BBB transport mechanisms to improve the effectiveness of antipsychotic medication, and (c) the value of therapeutic strategies aimed at protecting or repairing the BBB in psychosis [2]. Systematic preclinical investigations focusing on the extent of BBB transport of marketed and novel antipsychotics in brain regions of interest (ROI) will be needed to answer these questions. However, the scope for conducting such investigations is limited by the difficulty of quantitatively characterizing the extent of unbound drug delivery to the brain. In preclinical studies, methodological limitations often make it necessary to treat the BBB as a homogeneous interface, implying uniform brain-wide drug exposure. However, in reality, the BBB exhibits considerable structural and functional region-specific heterogeneity [8, 9], which may cause significant errors in the acquisition and interpretation of experimental data if not properly accounted for.

To understand the biological mechanisms of low-molecular-weight drug transport across the BBB, it is essential to recognize that only unbound (free) and nonionized molecules can cross the membrane to interact with targets in the brain and initiate a pharmacological response [10–13]. However, in both blood and brain compartments, drugs exist in both their unbound forms and in bound forms complexed with blood proteins or cell constituents [11]. Specific and sensitive analytical methods are needed to investigate the quantitative impact of multiple interrelated processes on unbound antipsychotic drug transport across the BBB at regional and subregional levels, where subtle differences may exist.

Current methods for investigating the transport of molecules across the BBB include in vivo positron emission tomography brain imaging [14], advanced microscopy [15], in situ brain perfusion [16], and cutting-edge in vitro cell culture models [17–19]. However, in vivo cerebral microdialysis [20] is the only technique that can be used to obtain samples from focal brain areas and blood containing only the unbound drug. This method also permits quantitation of the extent and predominant direction of BBB drug transport based on measurements of Kpu,brain, i.e., the ratio of the unbound drug’s concentration in the brain to that in the plasma. Unfortunately, the results of cerebral microdialysis analyses of specific brain regions...
cannot be directly extrapolated to other regions or the entire brain. Therefore, there is no available method that can provide definitive information on how much unbound drug enters the entire brain or individual brain regions and subregions from the blood at a given time point. However, such detailed knowledge of the pharmacokinetics at different regional target sites within the brain and their interactions is needed to clarify the relationship between unbound drug exposure and observed responses.

Methodological advances in neuropharmacokinetic (neuroPK) studies have enabled assessment of the net flux of substances across the BBB without confounding due to drug binding in the brain and plasma [21, 22]. This was made possible by the development of high-throughput brain-slice method for investigation of drug uptake and distribution into the brain tissue, which is characterized based on the unbound volume of drug distribution in the brain, V_ubrain. Because V_ubrain provides an in vivo-like estimate of the drug’s intra-brain distribution, this approach allows reliable interconversion of estimated total and unbound drug brain concentrations [23, 24]. The brain-slice method is an integral part of the combinatorial mapping approach (CMA), a toolbox for assessing intracellular and extracellular exposure of antipsychotics in the entire brain and discrete brain ROI [25]. The CMA was developed for screening and selection of new chemical entities and has expanded the scope of neuroPK studies [25, 26]. Unfortunately, it has a number of technical drawbacks, including low accuracy when applied to small regions.
anatomical structures in the brain. This limits the ability to acquire spatial information and makes it impossible to sample subregions or to obtain adequate sample volumes for drug bioanalysis when using conventional liquid chromatography-tandem mass spectrometry (LC–MS/MS).

Matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) enables powerful in situ two-(and three)-dimensional visualization of drugs, drug metabolites, lipids, peptides, and proteins in tissue samples and other matrices [27]. Recent improvements in the lateral resolution, speed, mass resolution, and sensitivity of mass spectrometers, as well as in bioinformatics tools, have enabled visualization of molecules even at subcellular levels [28]. Furthermore, the development of fully validated quantitative MSI (qMSI) methods [29] has allowed MSI techniques to be used in pharmaceutical research also with focus on the assessment of BBB drug transport [30–34]. We recently

Fig. 2 Illustration of the workflow for assessing total brain drug concentrations using qMSI-uD. a Cryosectioning of a brain tissue section (left) and a brain slice (right), collected and frozen after performing in vivo and in vitro experiments, respectively. Thaw-mounting of tissue slices on precooled indium tin oxide-coated glass slides and preparation of three technical replicates from consecutive tissue sections on additional glass slides. b Sample preparation for MALDI-qMSI. Spotting of calibration standard solutions of the drug and quality-control (QC) solutions on the top of the tissue. Automatic spraying of a deuterated analog of the drug onto the tissue as an internal standard (IS) followed by application of the MALDI matrix and acquisition of MALDI-MSI data. c Processing of the acquired data involves selection and visualization of ions of interest and normalization of the data against that for the IS. This is followed by determination of regions of interest (ROI) of calibration-standard spots and selected brain regions based on a reference brain atlas [50] generated using the same tissue sections after staining with hematoxylin and eosin. Finally, a calibration curve is created by plotting the drug’s concentration against the average intensity of the ion, and individual average ion intensities within the region of interest are exported and quantitated using the calibration curve.
developed a qMSI approach for investigating how drug–drug interactions influence drug transfer from the blood to small brain structures [35]. This showed that qMSI has applications outside compound mapping and can be used to identify relevant preclinical drug–drug interactions based on binding to specific transporter proteins. However, while existing qMSI methods can accurately determine the distribution of different pharmaceutical entities, they cannot discriminate between bound and unbound drug forms, and therefore can only quantitate total drug concentrations in tissues.

We here present a method, qMSI for unbound drug determination (qMSI-uD), that can be used to assess the extent of unbound drug transport across the BBB and intrabrain drug distribution in small anatomical regions including subregions. By using the power of MALDI-qMSI, we overcome the limitations of the CMA–ROI method and enhance its capabilities. We demonstrate the performance and validity of qMSI-uD using three antipsychotic drugs with different BBB transport properties and regional distribution patterns: risperidone, clozapine, and olanzapine revealing their unique BBB transport features. The method provides a label-free and multiplex approach for detailed mapping and visualization of the extent of regional unbound drug transport across the BBB. Moreover, it enables simultaneous detection and localization of drug metabolites with high lateral resolution. The ability to provide detailed information on unbound antipsychotic drug transport across the BBB and regional target-site exposure makes qMSI-uD a valuable tool for molecular psychiatrists engaged in investigation of various BBB drug transport-related hypotheses.

RESULTS
Overview of the concept
Drawing on the pharmacokinetic basis (see Methods), qMSI-uD enables detailed mapping of regional and subregional BBB drug transport based on \( K_{\text{p,uu,brain}} \) (Fig. 1 and Fig. 2). It combines two distinct experimental approaches, namely in vivo brain neuroPK and in vitro brain-slice drug-distribution studies (Fig. 1). The

---

**Fig. 3** Cross-validation of the LC–MS/MS and qMSI. a, b Scatter dot plots showing LC–MS/MS and MALDI-qMSI-based quantitation of steady-state total brain tissue and plasma concentrations and c, d the total brain slice and buffer concentrations collected after performing in vivo experiments \((n = 6 \text{ per group})\) and in vitro experiments \((n = 3 \text{ per group})\), respectively. \( K_{\text{p,brain}} \) (e) and \( K_{\text{p,uu,brain}} \) (f) values determined using the conventional CMA method (LC–MS/MS) and MALDI-qMSI. Error bars represent standard deviations from the mean. Total concentrations \((C_{\text{tot,brain,ss}})\) for the in vivo samples were analyzed in half of the brain (LC–MS/MS), and in the coronal section of the second half of the brain (MALDI-qMSI). Total concentrations \((C_{\text{tot,br.slice,ss}})\) from the in vitro study were analyzed either in the entire brain slice (LC–MS/MS) or in the coronal section of the brain slice (MALDI-qMSI). RISP risperidone, CLZ clozapine, OLZ olanzapine. NB: a semilogarithmic scale is used in panels b, c, e, and f.
in vitro rat brain-slice assay provides information on the intrabrain
distribution of an unbound drug but cannot provide quantitative
information on BBB transport, unlike in vivo data on drug
distribution in the brain. The central hypothesis underpinning qMSI-uD is that the ratio of the total brain steady-state
centrations obtained in neuroPK studies (in vivo) and rat
brain-slice studies (in vitro) reflects the magnitude and direction of
unbound drug transport across the BBB if the unbound drug
plasma concentration is equal to the buffer concentration (Eqs. 6
and 7). If the latter condition is not satisfied, i.e., the unbound drug
plasma and buffer concentrations are unequal in the steady state,
a correction factor must be applied to this ratio (Eq. 9). This may
be necessary if the BBB transport and intrabrain distribution of a
drug are concentration-independent in a given concentration
range. Moreover, using only in vitro rat brain-slice assay data, the
intrabrain distribution of an unbound drug can be characterized
based on the volume of distribution of unbound drug ($V_{u,brain}$),
which can be independently evaluated by determining the ratio of
the total concentration of the drug in the brain slice to the steady-
state buffer concentration.

The qMSI-uD concept builds on several implicit and explicit assumptions (see Methods) that define the conditions under
which it can be used and the validity of inferences drawn from the
results obtained. An important and unique advantage of absolute quantitation based on MALDI-qMSI analysis included in the qMSI-
uD method (Fig. 2) is that it can provide information on the spatial

---

**Fig. 4** Total brain concentrations determined by MALDI-qMSI. a Representative images showing the relative abundance and distribution of risperidone (left), clozapine (middle), and olanzapine (right) in in vivo and in vitro brain tissue sections. Representative images were measured with a lateral resolution of 40 µm and concentrations are shown using a logarithmic scale, scaled to 0–100% (the scale bar is 1 mm). Data for determination of total concentrations were acquired at 100-µm lateral resolution and normalized against a deuterated drug analogue. b Scatter dot plots of the total drug concentrations (ng g$^{-1}$) in entire brain sections from in vivo ($n = 6$ per group) and in vitro ($n = 3$ per group) experiments. c Scatter dot plots of region-annotated total concentrations obtained from in vivo neuroPK studies, and d in vitro rat brain-slice assays. The steady-state total concentrations achieved in vivo ($C_{tot,brain,ss}$) and in vitro ($C_{tot,br.slice,ss}$) are shown as a reference line with the mean ± the standard deviation from the mean (gray shaded area). cc corpus callosum, ec external capsule, aca anterior commissure, CgCx cingulate cortex, MCx motor cortex, SCx somatosensory cortex, InCx insular cortex, Pir piriform cortex, CPU caudate putamen, NAc nucleus accumbens, LS lateral septum. Only statistically significant differences ($P < 0.01$) are shown. Note the differences in scale in figures b–d.
bioanalytical methods based on US FDA guidelines [36] (Supplementary Table 1, 2 and Supplementary Fig. 2). Third, the bioanalytical methods were compared with conventional CMA (Eq. 5). The \( K_{\text{pu,brain}} \) values determined using these three approaches did not differ significantly (Supplementary Fig. 1). Second, the MALDI-qMSI method was validated by applying selected validation criteria for conventional CMA (Fig. 3). There were no significant differences between the two methods for total risperidone concentrations in brain tissues, plasma, and buffer samples. However, the total concentration of clozapine determined by MALDI-qMSI in brain-slice samples was 1.6-fold higher \((P = 0.022)\) than that determined by LC–MS/MS (Fig. 3c). A similar but more pronounced pattern was observed for both in vivo (1.7-fold, \( P = 0.002 \)) and in vitro (2.8-fold) brain samples containing olanzapine (Fig. 3a, c). To rule out the possibility that differences in ionization might give rise to differences in analyte quantitation between the two analytical methods, extracts of brain slices dosed with clozapine and olanzapine were analyzed by MALDI-qMSI. The concentrations of clozapine and olanzapine extracts determined using MALDI-qMSI did not differ significantly from those determined by LC–MS/MS \((P = 0.0508 \text{ and } P = 0.1087, \text{ respectively, for the two drugs})\). The cross-validation results thus suggest that measurements of total drug concentrations in the studied matrices (Fig. 3a–d) by MALDI-qMSI might depend on sample preparation, implying that the results obtained when analyzing whole-brain homogenates may differ from those for coronal brain sections. This would not affect the method’s usefulness for determining neuroPK parameters because the final results of such analyses are expressed as ratios of the values obtained from in vivo and in vitro samples. Importantly, the neuroPK parameters derived using qMSI-UD were similar to the reference CMA values for risperidone and clozapine, and differed from the CMA values by less than a factor of 1.5 for olanzapine (Fig. 3e, f). The method thus achieved good agreement with the conventional CMA approach, supporting its use for region annotation.

**MALDI-qMSI assessment of antipsychotic exposure in rat brain tissue**

Unbound drug transport across the BBB (Eqs. 7 and 8) was estimated (see Fig. 4) by comparing whole-brain and region-annotated steady-state concentrations of risperidone, clozapine, and olanzapine (Supplementary Table 3) in in vivo and in vitro samples (see Fig. 1). In this context, the term “whole brain concentration” means the concentration in an entire coronal brain section. Mean total drug concentrations measured by MALDI-qMSI in whole-brain sections from in vivo and in vitro experiments (Fig. 4a, b) were used as reference values in Dunnett’s multiple-comparison tests against region-annotated concentrations (Fig. 4c, d and Supplementary Table 4). In vivo exposures in the white matter regions (corpus callosum, external capsule, and anterior commissure) were significantly lower than the total whole-brain concentrations for all three drugs. The lowest concentration was detected in the corpus callosum (Supplementary Table 3). Additionally, the concentrations of risperidone, clozapine, and olanzapine in the insular cortex (a gray matter region) were 1.3-fold \((P = 0.0054)\), 1.2-fold \((P = 0.0004)\), and 1.5-fold \((P = 0.0014)\) higher, respectively, than the corresponding whole-brain concentrations (see Fig. 4c). The ratios of the region-annotated drug concentrations to the whole-brain total concentrations for the in vitro brain-slice experiments exhibited similar trends to those...
observed in the in vivo neuroPK study (Fig. 4d). Total concentrations do not reflect the extent of unbound drug transport across the BBB but are used to estimate it.

Mapping of unbound drug transport across the BBB in the brain regions and subregions

The extent of unbound drug transport across the BBB was estimated based on $K_{puu,brain}$ at the whole-brain level and $K_{puu,ROI}$ at specific regional levels using Eqs. 7–9. The determined total $K_{puu,brain}$ values of $0.10 \pm 0.02$ for risperidone, $0.31 \pm 0.03$ for clozapine, and $0.82 \pm 0.19$ for olanzapine agreed well with previous reports [26]. The spread of these values shows that the three selected drugs span the spectrum of BBB transport behaviors, from active efflux to passive transport. Furthermore, region-annotated mean $K_{puu,ROI}$ values obtained by qMSI-uD were used to build unique drug-specific visual maps of BBB drug transport (Fig. 5a–d) that enable at-a-glance scrutiny of BBB transport heterogeneity.

The three drugs had distinct patterns of BBB transport with a few commonalities (Supplementary Tables 5 and 6 and Supplementary Fig. 3). Olanzapine exhibited the most heterogeneous BBB transport, with predominant passive transport and potential uptake in the anterior commissure and somatosensory cortex (Fig. 5d, g). On average, the extent of BBB transport of olanzapine was lowest in the lateral septum: the $K_{puu,ROI}$ for this drug in the lateral septum was between 1.4-fold and 2.5-fold lower than in other brain regions (Supplementary Table 5 and 6c). Moreover, the differences in intraindividual region-annotated levels of olanzapine were more pronounced than the differences between individual animals. Unlike olanzapine, the BBB transport of clozapine did not differ greatly between the studied regions and subregions (Fig. 5b, e). Interestingly, cortical subregions exhibited greater variation in the extent of BBB transport of risperidone (Supplementary Table 5 and 6a), with the motor cortex having the most efficient efflux ($K_{puu,ROI} = 0.08 \pm 0.01$) and the piriform cortex the least efficient ($K_{puu,ROI} = 0.12 \pm 0.02$). Some further common trends were revealed by $K_{puu,ROI}$ mapping. The anterior commissure had the highest $K_{puu,ROI}$ for clozapine and olanzapine across all discrete regions, and the second highest for risperidone (Supplementary Table 5). Surprisingly, the opposite was observed in another white matter region, the corpus callosum, for which the efflux activity toward risperidone and olanzapine was greater than in other brain regions. These results show that our new method enables reliable estimation of unbound BBB transport in specific regions and subregions of the brain, as well as spatial visualization of intrabrain unbound drug distributions (Supplementary Fig. 5), which cannot be achieved by other means.

Localization of risperidone and its hydroxylated metabolite using high-resolution imaging

In addition to its capabilities in quantitative drug assessment, MALDI-qMSI could be used for simultaneous detection of drug metabolites and drug-target effects, as well as precise localization of drug metabolites using high-resolution imaging. To illustrate this capability, the distribution of risperidone and its active metabolite hydroxyl risperidone (Fig. 6 and Supplementary Fig. 4) were determined in the
striatum and lateral ventricle brain area (interaural 11.16 mm, bregma 2.16 mm). Risperidone and hydroxyrisperidone were most heavily accumulated inside the lateral ventricle, with 1.5-fold lower abundance in the surrounding ependyma (Fig. 6b, c) and the lowest abundance in the dorsal striatum (Fig. 6e, f). The striatal distribution of risperidone was more pronounced in the gray matter of the striatum than in neuronal fibers. Whereas the abundance of risperidone was the highest in the anterior commissure and lowest in the corpus callosum, the opposite was observed for hydroxy risperidone. Coupling qMSI-uD with high-resolution imaging will enhance the method’s capabilities, providing insights into BBB transport at the intraregional level. To illustrate the advantages of the MALDI-qMSI methodology in measuring drug-target effects using the same brain tissue material, we provide an example of the impact of risperidone on the dopaminergic system (Supplementary Fig. 6). The ability to quantify regional unbound drug exposure within the brain and simultaneously evaluate target-interaction effects enables a better understanding of the complex processes that regulate a drug’s concentration profile within the brain at the target site. The latter ability in particular presents new opportunities for molecular psychiatrists to clarify pharmacokinetic–pharmacodynamic relationships at the level of individual brain regions.

DISCUSSION
We have developed a method, qMSI-uD, that enables simultaneous determination and visualization of the extent of unbound pharmacologically active antipsychotic drug transport across the BBB ($K_{pu,brain}$) in small anatomical regions of the brain using MALDI-qMSI technology. The combination of two complementary experimental approaches that involve establishing pharmacokinetic equilibrium, namely in vivo neuroPK and in vitro brain-slice studies, allows the extent of unbound BBB transport of small-molecular-weight substances to be estimated using Eqs. 7 or 9. The resulting regional ($K_{pu,ROI}$) values are subsequently used to generate region-annotated maps showing the local extent and predominant direction of unbound drug transport across the BBB. In addition, qMSI-uD enables spatial visualization of intrabrain unbound drug distributions, which depend on specific and nonspecific drug brain tissue binding, pH partitioning, and cellular barrier transport. These distributions are characterized using the variable $V_{ubrain}$ [24], which can be used to estimate regional unbound drug concentrations in the interstitial fluid based on total concentrations obtained from in vivo neuroPK studies. The ability to simultaneously characterize both the extent of regional BBB drug transport and the post-BBB regional distribution of unbound drugs in the brain with high spatial resolution offers neuroscientists unprecedented opportunities to characterize, rank, and pharmacologically profile substances based on their neuroPK properties in specific target regions of the brain. The proposed approach could also potentially be applied to nonbrain tissues, further extending its applicability.

The BBB is a highly specialized and selective interface consisting of brain microvascular endothelial cells with tight junctions surrounded by an intricate milieu of astrocyte end feet and pericytes [37]. Its microvasculature topology, neurovascular cellular composition, and endothelial biochemical characteristics are all region-specific and heterogeneous [8, 9, 38]. Endothelial dysfunctions in the BBB are widely accepted to play central roles in the development and progression of several neurological diseases including SZ [39]. Abnormalities of capillaries and their microenvironment in the prefrontal and visual cortices in SZ brains include thickening of the basal lamina, prominent swelling of astrocytic end feet, and signs of microglial activation [6]. Molecular alterations in brain endothelial cells in the prefrontal cortex in SZ patients include elevated levels of intercellular adhesion molecule-1 and VE-cadherin mRNA, and exacerbated reductions in the levels of breast cancer resistance protein in the “high inflammation” SZ subgroup [7]. In addition, positron emission tomography experiments showed that patients with chronic SZ under treatment with antipsychotics exhibited significantly reduced 11C-verapamil uptake at the brain regional level. This was probably related to an increase in the activity of the P-glycoprotein (P-gp) pump [4]. Despite the growing evidence of structural and functional heterogeneity in the BBB and its role in mental disorders, most existing analytical methods cannot be used to study functional aspects of BBB drug transport because they are only capable of determining total drug concentrations. This limitation is overcome by qMSI-uD, which can be used to probe the BBB transport of any substance of interest; it is not limited to drugs and drug candidates.

Using qMSI-uD we demonstrated differences in the extent of BBB drug transport within the gray and white matter for three antipsychotics: risperidone, clozapine, and olanzapine. These drugs exhibited a wide range of BBB transport properties, including both efficient efflux and active uptake. The heterogeneity of the BBB has previously been shown to play a key role in the regional transport of unbound antipsychotics.

The MALDI-qMSI method enabled visualization of regional and subregional differences within coronal rat brain tissue sections for risperidone, clozapine, and olanzapine after drug exposure in vivo and in vitro. The concentrations of the drugs in white matter were found to be up to three times lower than in gray matter. The total concentration of a drug in a given region of the brain, i.e., the sum of the unbound and bound drug concentrations (the latter of which depends strongly on blood exposure), is closely associated with the restrictive function and heterogeneity of the BBB [8], the spatial expression of transporters and receptors [38], and specific and nonspecific drug binding in the brain parenchyma [25, 40]. The lack of a functional BBB in the brain-slice preparation only allows drug uptake and binding to brain tissue to be evaluated. This is why the measured drug exposure in the in vitro brain slices was higher than in the in vivo brain tissue samples. Previous studies [25, 26] have shown that the $K_{pu,brain}$ is a key parameter for measurement of drug BBB transport because it reflects the brain availability of the pharmacologically active unbound drug. The value of $K_{pu,brain}$ also indicates the dominant process by which the unbound drug passes across the BBB: if $K_{pu,brain} < 1$, efflux dominates; if $K_{pu,brain} = 1$, passive transport dominates; and if $K_{pu,brain} > 1$, the drug is actively taken up. Previously reported $K_{pu,brain}$ values for risperidone, clozapine, and olanzapine agree well with our results, differing by less than a factor of two [26]. Regional differences in $K_{pu,ROI}$ have been demonstrated —specifically, the value for the frontal cortex was reported to be higher than that for the caudate putamen brain region in the cases of risperidone, clozapine, and olanzapine [25]. The caudate putamen $K_{pu,ROI}$ values obtained in this work agree with those reported previously [25], but the $K_{pu,ROI}$ values for individual cortex subregions were similar to those for the caudate putamen. These contrasting results could be due to differences in experimental design: the doses of risperidone and olanzapine used in this work were ca. 10- and 3-fold higher, respectively, than those used in the previous study, which may have caused saturation of BBB transporters in this work. Differences in tissue sampling and sample-preparation procedures may also have contributed to the difference in results: whereas the previous study examined homogenates of the entire frontal cortex, we examined coronal sections and divided the cortex into individual subregions. Furthermore, drug transport across the BBB can be highly region-dependent due to the heterogeneity of brain microvasculature [41] and the variation in the density of transporters and receptors along the BBB [38]. In addition, the relatively high total concentrations of risperidone and its metabolite observed in the lateral ventricle could be due to structural, biochemical, and functional differences between the BBB and BCSFB (Fig. 6) [42]. A similar distribution was previously observed by MSI for loperamide, another known P-gp substrate [35].
BBB drug transport is driven by several processes and depends on the number of functional transporters that exist per unit of capillary surface area. However, transporter density differs between brain regions and subregions [9, 43, 44], and the degree of bifurcation, vascular density, and vessel length all differ between cortical subregions [41]. For example, the corpus callosum, external capsule, and lateral septum regions have some of the lowest vascular densities and vessel lengths among mouse brain regions, which may influence the number of available transporters at the BBB per unit surface area [9, 41]. We found that the BBB efflux of clozapine and olanzapine was appreciably stronger in the lateral septum than in other brain regions, while the highest efflux activity for risperidone and olanzapine was in the corpus callosum subregion. It should also be noted that although the total drug concentrations in the corpus callosum were low, this region had some of the highest K\text{p,uu,ROI} values observed in this work. Conversely, the highly vascularized perirhinal cortex had the lowest net efflux of P-gp substrate risperidone at the BBB. The latter could be related to the local expression of efflux transporters, yet the lack of correlation between the expression of the P-gp transporter and its activity has been also documented [45]. Interestingly, the anterior commissure had some of the highest K\text{p,uu,ROI} values for all of the tested drugs. The role of regional expression of BBB drug transporters becomes obvious also in relation to the pathophysiology of SZ as well as development of the resistance or increased sensitivity to antipsychotic treatment [4, 5, 46]. At present, there is very little quantitative data on the regional and subregional expression of transporters along the capillaries in normal and SZ brain, as well as in the course of antipsychotic treatment [7, 37, 38, 47]. Data on regional transporter expression could help explain regional differences in the BBB transport of unbound drugs.

Because drug transport across the BBB is so sensitive to its heterogeneity in different brain regions, there is a clear need for robust advanced imaging methods that can reveal the spatial distribution of drugs and their metabolites in the brain. To implement qMSI-uD, it is necessary to satisfy some pharmacokinetic and qMSI-related criteria (as discussed in the Methods section). In particular, it is essential to establish pharmacokinetic equilibrium under all experimental conditions and to optimize the administered doses and concentrations of each drug. Additionally, qMSI requires that all prospective analytes be ionizable with suf

**Chemicals**

Clozapine, olanzapine, clozapine-d\textsubscript{4}, risperidone-d\textsubscript{4}, olanzapine-d\textsubscript{8}, 2-hydroxypropyl-β-cyclodextrin (HP\textsubscript{B}CD), 4-(2-hydroxyethyl)-1-piperazin

**Animals**

All experiments were performed on drug-naive male 250-300 g Sprague–Dawley rats (Tacoi, Lille Skensved, Denmark) in accordance with the guidelines of the National Board for Laboratory Animals, and were approved by the Animal Ethics Committee of Uppsala, Sweden (ethical approvals C189/14). All rats were housed in groups at 20–22 °C and 45–65% humidity, under a 12-h light/dark cycle with ad libitum access to food and water. All neuroPK experiments were performed after one week of acclimatization.

**In vivo neuroPK studies**

The plasma and CNS exposure of the three antipsychotic drugs risperidone, clozapine, and olanzapine were assessed in vivo under steady-state conditions. The minimally required per group sample size for a two-tailed t-test study was estimated to be six, given the probability level (α = 0.05), the anticipated effect size (Cohen’s d = 1.5), and the desired statistical power level (0.8) [49]. Hence, 24 drug-naive rats were included in in vivo neuroPK studies, i.e., six rats per drug or vehicle. Animals were not randomized, and the study was not blinded.

The optimal dose for each drug was determined based on prior knowledge [25] and pilot experiments (n = 1 rat per drug, data not shown). A total plasma concentration of 100 ng mL\textsuperscript{-1} was targeted during optimization of the total brain concentration under steady-state conditions. Due to the comparatively low sensitivity of MSI detection of olanzapine and risperidone, the doses of these drugs were increased. The final total doses were 7.7, 2.5, and 5 mg kg\textsuperscript{-1} for risperidone, clozapine, and olanzapine, respectively.

Each rat’s femoral vein and artery was surgically catheterized one day before the experiment under isoflurane anesthesia. After that, they were individually placed in a CMA120 system (CMA, Solna, Sweden) for freely moving animals with ad libitum access to food and water. The drugs were administered individually in 10% hydroxypropyl beta-cyclodextrin in saline for parenteral use (Uppsala University Hospital Pharmacy, Uppsala, Sweden) as a fast-rate infusion for 5 min followed by a 4-h constant slow-rate intravenous infusion, using a flow rate of 1 mL kg\textsuperscript{-1} h\textsuperscript{-1}. One group (n = 6 rats) was used as vehicle controls and received 10% hydroxypropyl beta-cyclodextrin in saline for 4 h, using the flow rate applied during drug administration. Blood samples (300 µL) were taken from a femoralis before the start of the infusion and at its termination. Plasma samples were obtained after centrifugation at 4 °C for 5 min at 10,000 rpm and were stored at −80 °C pending bioanalysis. At the end of the experiment, the rats were anesthetized by inhalation of 5% isoflurane (Abbot Scandinavia, Solna, Sweden) for at most three min and decapitated. The brains were rapidly removed, cut sagittally to separate the right and left hemispheres, and immersed in isopentane that had been prechilled on dry ice for 10 s. Subsequently, the brain samples were covered with aluminum foil and placed on dry ice. Samples were stored at −80 °C pending bioanalysis by LC–MS/MS and MSI.

**In vitro brain-slice assay**

The unbound volumes of distribution of the antipsychotic drugs in brain (V\textsubscript{u,brain}, mL g brain\textsuperscript{-1}) were estimated using the brain-slice method according to previously published protocols [23, 24] with modifications described below. V\textsubscript{u,brain} reflects the extent of drug binding and uptake into brain parenchymal cells.

To evaluate the possibility of using brain slices after incubation for further cryosectioning as required for MSI analysis, several pilot experiments were performed to identify a suitable slice thickness and duration of incubation to enable equilibration of the drug between the brain-slice interstitial fluid and the buffer in the beaker without reducing the integrity or quality of the slices. In the optimized procedure, five 500-µm brain...
coronal slices (from the area of rostral striatum) were obtained from each drug-naive rat brain (n = 3 per group) using a vibrating blade microtome Leica VT1200 (Leica Microsystems AB, Sweden). The brain slices were then transferred into one 0.8-mm flat-bottom glass beaker containing 15 mL of preoxygenated artificial extracellular fluid (aECF) containing the drug of interest at a final concentration of 200 nM. The slices were incubated for 3 h at 37 °C in a shaker (MaxQ4450 Thermo Fisher Scientific, NinoLab, Sweden) with a rotation speed of 45 rpm and a constant oxygen flow of about 75–80 mL per min through a glass frit. The beaker was covered with a custom-fabricated lid fitted with a Teflon fluorinated ethylene-propylene film (Teflon FEP film 50 Å, 12.7-μm thickness) to allow oxygen exchange and prevent evaporation of the aECF. The pH of the aECF was measured immediately after the 3-h incubation to ensure that it remained within the acceptable range (7.4 ± 0.15). This criterion was satisfied in all experiments. Brain slices from three other rats were incubated in blank aECF under otherwise identical conditions to obtain control brain tissue samples for the MALDI-qMSI analysis. Brain slices and aECF were sampled at the end of the 3-h incubation. The recovery and thermostatting of the investigated drugs were assessed by sampling the aECF buffer before and after the 3 h incubation. The recovery and thermostatting of all three drugs exceeded the acceptable minimum value of 70% (data not shown). All aECF samples were mixed with blank brain homogenate in a ratio of 1:4 (w/v) and stored at −80 °C pending bioanalysis by LC–MS/MS and MALDI-qMSI. One brain slice from each experiment was sampled for LC–MS/MS analysis. The slices were individually weighed and homogenized in aECF (1:9, w/v) using a VVCX-130 TM sonicator processor (Sonic, Chemical Instruments AB, Sweden) and stored at −80 °C pending bioanalysis. The four remaining brain slices from each experiment were used for MALDI-qMSI analysis. The following handling procedure was applied to ensure preparation of high-quality slices suitable for subsequent cryosectioning. First, brain slices were individually transferred to parafilm with a minimal volume of aECF on a spatula and delicately flattened using a brush. Second, the excess buffer was aspirated by gently applying vacuum on the edges of the slice. Thereafter, the flattened brain slice on parafilm was placed on a metal plate that had been prechilled on dry ice and covered with 0.6 mL of ice-cold isopentane. The frozen slices were then immediately placed on dry ice and stored at −80 °C pending MALDI-qMSI analysis.

The concentrations of the drugs in the virtually protein-free aECF at equilibrium were assumed to be equal to their concentration in the interstitial fluid of the brain slices. Therefore, $V_m_{\text{brain}}$ (mL g brain$^{-1}$) was estimated using Eq 1 as the ratio of the amount of compound in the brain slice ($A_{\text{brain}}$ ng g brain$^{-1}$) to the measured final unbound concentration of the drug in the aECF ($C_{\text{buffer}}$ ng mL$^{-1}$).

$$V_m_{\text{brain}} = A_{\text{brain}} / C_{\text{buffer}}$$

(1)

Here, $V_m$ (mL g brain$^{-1}$) is the volume of the aECF layer surrounding the brain slices, and was estimated to be 0.094 mL g brain$^{-1}$ using [14C]inulin as a marker [23]. NB: the impact of the microvasculature on the measurement of the overall uptake of a drug by brain parenchymal cells is negligible. The mean drug concentrations in the buffer after incubating the brain slices for 5 h were on average twice the mean unbound brain interstitial fluid concentrations in vivo. This rules out any potential concentration-dependent differences in intrabrain drug distribution between the in vivo and in vitro settings.

Since the process of preparing the brain slices for MALDI-qMSI analysis eliminated the possibility that the buffer layer could quantitatively affect the estimation of the total drug concentration in the brain slices, Eq. 2 was used to calculate $V_m_{\text{brain}}$:

$$V_m_{\text{brain}} = (C_{\text{brain, slice}} / C_{\text{buffer}}) - 1$$

(2)

Here, $C_{\text{brain, slice}}$ (ng g brain$^{-1}$) is the total amount of the drug in the coronal brain slice measured using MALDI-qMSI. High $V_m_{\text{brain}}$ values indicate extensive drug tissue binding and/or uptake.

MALDI-qMSI sample preparation

The MALDI-qMSI-based sample analysis is illustrated in Fig. 2. The frozen brain tissues and brain slices were cryo-sectioned using a Leica CM1900 UV cryostat-microtome (Leica Microsystems, Wetzlar, Germany). After conditionining of the samples in the cryochamber at −20 °C for 1 h, consecutive 12-μm-thick coronal brain sections of the brain tissues were cut at the striatal level and thaw-mounted on a precooled conductive indium tin oxide-coated glass slide (Bruker Daltonics, Bremen, Germany). Brain tissues from the in vivo studies were mounted next to one another on the same slide to minimize variation due to matrix application and MSI data acquisition. The same approach was used for brain tissue slices originating from the in vitro experiments. Three sequential slides for each sample set (in vivo and in vitro) were prepared for use as technical replicates. To enable cryosectioning of the 500-μm brain tissue slices, they were mounted in icy water on a flat gelatin block and frozen prior to sectioning. The prepared slides were stored at −80 °C.

On the day of measurement, the tissue sections were vacuum-desiccated for 40 min prior to application of the calibration standards and quality-control samples, after which they were optically imaged with a photo scanner (Epson Perfection V500). To quantify the drug in the tissue, calibration solutions (40 nL of 25, 50, 100, 250, 500, and 1000 ng mL$^{-1}$) and quality-control samples were spotted on the top of the brain cortex and/or striatum regions of the control tissues. These solutions contained low (25 ng mL$^{-1}$), intermediate (100 ng mL$^{-1}$) for risperidone or 250 ng mL$^{-1}$ for clozapine and olanzapine), or high concentrations (500 ng mL$^{-1}$ for risperidone or 1000 ng mL$^{-1}$ for clozapine and olanzapine) of the appropriate drug in 50% ethanol with 0.2% TFA and were applied using a BioSpot BT600 automatic spotter (BioFluidix, Freiburg im Breisgau, Germany).

Solutions of risperidone-$d_6$ (30 ng mL$^{-1}$), olanzapine-$d_6$ (40 ng mL$^{-1}$), and clozapine-$d_5$ (55 ng mL$^{-1}$), all prepared in 50% acetonitrile with 0.2% TFA, were used as internal standards and were sprayed on top of the tissue sections with an automated data collection system (HTX-Technol, Charlotte, NC, USA) prior to application of the MALDI matrix. The concentration of the internal standard was chosen to match the average signal intensity of the corresponding drug in the relevant brain tissue sections. The internal standard solution was sprayed over the samples under the following conditions: the nozzle temperature of the spray head was set at 90 °C and the reagents were sprayed pneumatically (6-psi N2) with a flow rate of 70 μL min$^{-1}$ and a linear nozzle velocity of 110 cm min$^{-1}$ in six passes (alternating horizontal and vertical deposition) with 2-mm track spacing. Subsequently, 2,5-dihydroxybenzoic acid MALDI matrix (35 mg mL$^{-1}$ in 50% acetonitrile with 0.2% TFA) was sprayed with a spray head temperature of 95 °C and a linear nozzle velocity of 120 cm min$^{-1}$ in eight passes with 3 mm track spacing. For high-resolution imaging, the matrix solutions were prepared in 60% acetonitrile with 0.2% TFA.

Drug concentrations in plasma and buffer samples were also measured using the LC–MS/MS protocol described below. The supernatants (10 μL) of extracted plasma and buffer samples, as well as calibration standards and quality-control samples, were diluted with 20 μL of 0.2% TFA and vigorously vortexed. Afterward, 0.5 μL of each sample was spotted manually on a MALDI ground steel plate in triplicate. The supernatants of risperidone plasma samples were diluted tenfold to ensure that their drug concentrations were below the relevant upper limit of quantitation (ULOQ), i.e., below 1000 ng mL$^{-1}$. The prepared MALDI plate was then sprayed with 2,5-dihydroxybenzoic acid (35 mg mL$^{-1}$ in 50% acetonitrile with 0.2% TFA) using the TM sprayer with the same application method as for the tissue samples. Internal standards of all drugs were included in the extraction procedure (see LC–MS/MS section). Therefore, there was no need for additional internal standard spraying.

MALDI-qMSI analysis and data processing

All MSI experiments were performed using a MALDI Fourier-transform ion cyclotron resonance (FTICR) mass spectrometer (solarisX 7.7 2T, Bruker Daltonics, Bremen, Germany) equipped with a Smartbeam II 2-KHz laser and operated in positive-ion mode. The operating conditions (ion transfer, laser power, and laser focus) were adjusted separately for each measured drug to maximize the signal of the relevant parent ion before the first data acquisition and then kept constant throughout the analysis of the complete sample set. All data were acquired in continuous accumulation of selected ion (CASi) mode with a 160-Da mass window in the mass range 150–600 m/z (CASi 340–500 m/z) for risperidone and 100–600 m/z (CASi 220–380 m/z) for olanzapine and clozapine, via a 30-ns laser shot per spot. Brain tissue (n = 6,600, n = 1 control) and brain slice (n = 3 drug-treated, n = 1 control) sections were analyzed in one day and in random order to prevent possible bias due to potential factors such as matrix degradation or variation in mass spectrometer sensitivity. All samples were measured in three technical replicates on three consecutive days. Triflicates of plasma samples of each sample set were analyzed and their data were averaged. All tissue samples of each sample set were analyzed on different days. Tissue data were acquired with 100- or 40-μm raster steps. For plasma and buffer data acquisition, a 150-μm raster step...
was used. High-resolution images were acquired with a 20-µm lateral resolution. The acquired data were normalized against the data for the relevant deuterated analog and visualized using fleximaging software (Bruker Daltonics, v.5.0). Quantitative assessment of the tissue data was accomplished using msiQuant software (v.2.1.1.20), taking into account the density of the rat brain tissue (1.027 g cm$^{-3}$) and the thickness of the sections (12 µm), after converting the fleximaging data to msiQuant format using the msiQuant converter tool (FI 402 Reader to msiQuant). The results for specific brain regions were extracted after drawing the regions manually based on a rat brain atlas [30]. For olanzapine, clozapine, risperidone, and their deuterated analogs, m/z values were extracted using windows of 1 mDa and 1.5 mDa, respectively. MALDI-qMSI data for plasma and buffer samples were processed using the SCiLS software package (v.2020a Pro, Bruker). For each analyte, the average ion intensity within the ROI (either whole tissue section or a specific brain region) was used for data exploration. For the plasma and buffer matrices, areas under the curve were used instead of maximum intensities. This option was chosen after loading the raw data into SCiLS. To generate calibration curves, the calibration standards, quality-control samples, and blanks were measured three times: before, in between, and after the acquisition of brain tissue samples. The same approach was used for plasma and buffer samples.

**Morphological evaluation for MALDI-MSI**

After MALDI-MSI analyses, tissue sections were subjected to either Nissl staining or chloroform wash. Briefly, Nissl staining was performed by quickly washing with absolute ethanol to remove the MALDI matrix. The tissues were then fixed with two absolute ethanol washes of 5 min each and allowed to dry for another 5 min. After a subsequent one-min wash in water, tissues were stained with cresyl violet acidic solution (0.22% of acetic acid in water) for 10 min. Excess stain was removed by washing for 5 min in water, 3 min each in 90% and 95% ethanol, and then 3–3 min in absolute ethanol. For chloroform washing, the slide was placed in anhydrous chloroform for 30 s after MALDI matrix removal and then left to dry at room temperature. Images of stained or chloroform-washed tissues were overlaid on the MS images to facilitate annotation of brain regions. After high-resolution imaging, the tissues were stained with hematoxylin and eosin as follows. The MALDI matrix was removed and the tissues were washed with 95% ethanol for 30 s, 70% ethanol for 30 s, and deionized water for 2 min. Then, the tissues were stained with hematoxylin for 3 min. Excess stain was removed by washing in running tap water for 10 min, after which counterstaining with 1.5% eosin solution in 70% ethanol was performed for 30 s. The final removal of excess stain was performed by washing for 30–30 s in 70% ethanol, 30 s in 95% ethanol, and 5 min in absolute ethanol.

**LC–MS/MS sample preparation**

Acetonitrile-mediated protein precipitation (water: acetonitrile, 1:3, v/v) was performed for all matrices, i.e., brain homogenate (1:9 in aEFC) and plasma. Standards and quality-control samples were then prepared in each matrix. The deuterated analog approach was used to be analyzed separately. The matrix were pooled and processed as a single sample. A suitable dynamic range was attained for all analytes. The concentration range, based on at least six standard concentrations in the standard curves, was 10–1000 ng mL$^{-1}$ in plasma and 5–1000 ng g$^{-1}$ for brain homogenates. Quality-control samples with low (50 ng mL$^{-1}$ and 5 ng g$^{-1}$), intermediate (200 ng mL$^{-1}$ and 20 ng g$^{-1}$), and high (1000 ng mL$^{-1}$ and 100 ng g$^{-1}$) levels were prepared in plasma and brain matrices, respectively. Briefly, 25 µL of samples, blanks, quality controls, and standards were precipitated using 75 µL of ice-cold 0.2% FA in acetonitrile containing 50 ng mL$^{-1}$ of olanzapine-$d_{4}$, 50 ng mL$^{-1}$ of clozapine-$d_{4}$, and 10 ng mL$^{-1}$ of risperidone-$d_{4}$. The precipitated samples were vigorously vortexed and centrifuged for 3 min at 13,000 rpm. Thereafter, 25 µL of the supernatant was dried with 200 µL of a mixture of 0.1% FA as an elution solvent and MPA. For plasma samples obtained after in vivo administration of risperidone, the supernatant was additionally diluted four times to be below ULOQ. About 1.5 – 2 µL of the sample was injected onto an ACQUITY UPLC BEH C18 1.7 µM (2.1 × 50 mm) (Waters Corporation, Taunton, Massachusetts, USA) column.

**LC–MS/MS analysis and data processing**

The bioanalysis of samples from both in vivo and in vitro studies was performed using reversed-phase ultra-performance liquid chromatography (UPLC) (ACQUITY, Waters Corporation, Taunton, Massachusetts, USA) followed by tandem mass spectrometry (XEVO TQ-S micro, Waters, UK). Detection and quantitation of analytes were performed using multiple-reaction monitoring (MRM) to monitor parent → product ion (m/z) transitions (Supplementary Table 7) in positive electrospray (ES+) ionization mode. The source-dependent parameters used for all compounds were: capillary voltage: 1.0 kV, source temperature: 150°C, desolvation temperature: 350°C, desolvation gas flow: 10 L h$^{-1}$, and cone gas flow: 10 L h$^{-1}$. The mobile phases used to detect risperidone, clozapine, olanzapine, and the corresponding internal standards were MPA and 90% acetonitrile in 0.1% FA as elution solvent B (MPB), and were delivered at 0.3 mL min$^{-1}$. Gradient elution was performed using the following steps: (i) a step gradient from 10% MPB to 50% MPB from 0 to 4.5 min, (ii) a step gradient from 50% MPB to 100% MPB from 4.5 to 4.7 min, and (iii) 100% MPB from 4.7 to 5.2 min, followed by (iv) reequilibration of the column with 10% MPB from 5.2 to 5.5 min. Sample preparation and quantitation were performed using MassLynx 4.2 and TargetLynx (Waters, UK), respectively. The lowest nonzero standard in the calibration curve was defined as the lower limit of quantification (LLOQ). Blanks, calibration curves and quality controls were included in all analytical runs. All standard curves weighted as 1/$x^{2}$ were accepted at $R^{2}$ values ≥ 0.9. Standard deviations for the responses of internal standards were below 6% in all analytical runs. Over 90% of quality controls were within ± 10% of the nominal values.

**Validation and cross-validation of qMSI-UD**

The qMSI-UD method was validated in terms of linearity and range, coefficient of determination ($R^{2}$), limit of detection (LOD), within-run and interday accuracy, and precision, selectivity, and specificity by applying the requirement criteria specified in the American authorities’ guidelines for the validation of bioanalytical methods [36]. For data evaluation, a linear-regression model was used, tested using the F-test, and accepted at $Significance F < 0.05$. Limits of detection (LOD) were calculated using the LINEST function based on the expression $LOD = 3.3 σ/ΔS$, where $S$ is the slope of the calibration curve and $σ$ is the standard deviation of the y-intercept. Limits of quantitation (LOQ) were defined as the lower limits of quantitation (LLOQ) for tissues, which were taken to equal the concentration of the most dilute calibration standard giving a nonzero signal. The LLOQs for risperidone, clozapine, and olanzapine were 103, 115, and 113 ng g$^{-1}$, respectively. For plasma, LLOQs of 50 (risperidone), and 10 ng mL$^{-1}$ (clozapine and olanzapine) were accepted, while an LLOQ of 5 ng mL$^{-1}$ was applied for all three drugs in plasma. The method’s selectivity was evaluated using blank and LLOQ samples spotted on tissue samples. Specificity was evaluated based on the resolving power of the FTICR instrument. Within-run and interday accuracy and precision were evaluated for tissue samples based on relative standard deviation (RSD) of low (103, 115, and 1144 ng g$^{-1}$ for risperidone, clozapine, and olanzapine, respectively) and high (411, 1147, and 4579 ng g$^{-1}$) level quality control (QC) samples, reflecting a relevant concentration range closer to the expected experimental total concentrations for each drug. Within-run accuracy and precision for plasma samples were evaluated based on the RSDs of low (50 ng mL$^{-1}$) and high (200 ng mL$^{-1}$) level QC samples. For buffer, the low levels for QC samples were chosen as 5 ng mL$^{-1}$ (risperidone and clozapine) and 100 ng mL$^{-1}$ (olanzapine), and the high levels were 100 ng mL$^{-1}$ (risperidone and clozapine) and 1000 ng mL$^{-1}$ (olanzapine). Stability was evaluated for 24 and 72 hours during and between the measurements based on the RSDs of all measured standard solutions.

**Pharmacokinetic basis for mapping the regional and subregional transport of an unbound drug across the BBB using MALDI-qMSI**

The extent of drug transport across the BBB is characterized by the pharmacokinetic parameter $K_{pu\text{,brain}}$ [11, 12], i.e., the ratio of the unbound drug concentration in the brain to that in the plasma. This parameter measures the net flux of the unbound drug across the BBB, and its magnitude indicates the direction and efficiency of the BBB transport processes. If $K_{pu\text{,brain}}$ exceeds unity, the dominant transport process at the BBB is active uptake, whereas a value below unity indicates predominant efflux. $K_{pu\text{,brain}}$ is computed using the following expression:

$$K_{pu\text{,brain}} = \frac{AUC_{\text{brain}}}{AUC_{\text{plasma}}}$$

(3)

Here, $AUC_{\text{brain}}$ and $AUC_{\text{plasma}}$ are the areas under the curve (AUC) of the unbound drug concentration—time profile for the brain and the...
plasma; alternatively, $C_{\text{U,brain}}$ and $f_{\text{U,plasma}}$ (the steady-state unbound drug concentrations in the brain and plasma) can be used.

The CMA is a method for evaluating the extent of BBB transport based on $K_{\text{p,brain}}$ that has proven to be effective in the evaluation and selection of novel CNS drug candidates [26]. Importantly, it can also be used to estimate the extent of BBB transport in specific regions of interest (ROI) within the brain [25]. The methodological platform of CMA–ROI includes (i) in vivo neuroPK studies performed in rodents followed by measurement of partitioning coefficients ($K_{\text{p,ROI}}$) in discrete brain regions, (ii) in vitro drug tissue-binding studies for determination of the fraction of unbound drug in plasma ($f_{\text{U,plasma}}$), and (iii) in vitro brain slice studies for evaluation of the unbound volume of distribution in discrete brain regions ($V_{\text{U,ROI}}$). The extent of unbound drug transport across the BBB in the various CNS regions ($K_{\text{p,ROI}}$) is then determined from the experimentally determined $K_{\text{p,ROI}}$, $V_{\text{U,ROI}}$, and $f_{\text{U,plasma}}$ using the following equation:

$$K_{\text{p,ROI}} = \frac{V_{\text{U,ROI}}}{f_{\text{U,plasma}}}$$

(4)

where $K_{\text{p,ROI}}$ is the ratio of the total CNS regional concentration of the drug to its total plasma concentration under steady-state conditions.

Unfortunately, $K_{\text{p,uu,ROI}}$ cannot be estimated in small regions and subregions due to multiple methodological and technical problems, including the difficulty of dissecting small regions and performing bioanalysis with the resulting low sample volumes. By qMSI-uD approach, we overcome existing limitations. The underlying hypothesis of qMSI-uD is that the ratio of the total brain concentrations obtained from the in vivo neuroPK study and the in vitro brain-slice assay corresponds to the extent of BBB transport of the unbound drug (Fig. 1).

Rewriting the second part of Eq. 3 by representing $C_{\text{U,brain}}$, as the quotient of $C_{\text{tot,brain},ss}$ and $V_{\text{U,brain}}$ we obtain:

$$K_{\text{p,brain}} = \frac{C_{\text{tot,brain},ss}}{V_{\text{brain}} - C_{\text{plasma,ss}}}$$

(5)

By incorporating Eq. 2, Eq. 5 can be rewritten as

$$K_{\text{p,brain}} = \frac{C_{\text{total,brain},ss}}{C_{\text{U,brain}}} - C_{\text{U,buffer,ss}}$$

(6)

When the unbound plasma and buffer concentration are equal, Eq. 6 reduces to:

$$K_{\text{p,brain}} = \frac{C_{\text{total,brain},ss}}{C_{\text{buffer,ss}}}$$

(7)

When applied to a specific region of interest in the brain, Eq. 7 becomes

$$K_{\text{p,ROI}} = \frac{C_{\text{total,brain},ss}}{C_{\text{buffer,ss}}}$$

(8)

If the plasma and buffer concentrations of the drug differ, a correction factor (CF) must be computed and applied. If $K_{\text{p,uu,ROI}}$ and $V_{\text{U,brain}}$ are concentration-independent within the concentration range of interest, the CF can be taken to be the ratio of the unbound plasma and buffer concentrations, which can be determined in an independent experiment.

$$K_{\text{p,ROI}} = \frac{C_{\text{total,brain},ss}}{C_{\text{buffer,ss}}}$$

(9)

The method relies on several implicit and explicit assumptions, which are presented below. These assumptions define the method’s boundaries and the validity of any inference drawn from the obtained results. One of the method’s implicit assumptions is that steady-state conditions are established in both experimental settings. Because any violation of this assumption will significantly affect the results obtained, the achievement of a steady state must be confirmed experimentally in both settings. Of the explicit assumptions arising from heuristic principles, the most critical ones are (i) low-molecular-weight drugs (ca. 500 Da) are transported in accordance with the free-drug hypothesis, i.e., only unbound and nonionized molecules can cross membranes, (ii) only unbound drug is present in the virtually protein-free brain interstitial fluid (SSF), (iii) overall CNS drug disposition is not affected by brain drug metabolism and brain bulk flow, and (iv) the BBB transport and intra-brain distribution of a drug is concentration-independent in the concentration range of interest, enabling the application of a correction factor according to Eq. 9 if needed. The proposed method is thus valid for small-molecular-weight drugs that satisfy these assumptions.

**REFERENCES**

1. Kealy J, Greene C, Campbell M. Blood-brain barrier regulation in psychiatric disorders. Neurosci Lett. 2020;726:133664.
2. Pollak TA, Drndarski S, Stone JM, David AS, McGuire P, Abbott NJ. The blood–brain barrier in psychosis. Lancet Psychiatry. 2018;5:79–92.
3. Shaley H, Serlin Y, Friedman A. Breaching the blood-brain barrier as a gate to psychiatric disorder. Cardiovascular Psychiatry Neurol. 2009;2009:278531.
4. de Klerk OL, Willemen MP, ATOM, Boeker FJ, Bartels AL, Hendriks NH, den Boer JA, et al. Regional increase in P-glycoprotein function in the blood-brain barrier of patients with chronic schizophrenia: A PET study with [11C]verapamil as a probe for P-glycoprotein function. Psychiatry Res Neuroimaging. 2010;183:151–6.
5. Sekhar GN, Fleckney AL, Boyanova ST, Rapawala H, Lo R, Wang H, et al. Regional-specific blood-brain barrier transporter changes leads to increased sensitivity to amisulpride in Alzheimer’s disease, Fluids Barriers CNS. 2019;16:38.
6. Uranova NA, Zimina IS, Vlkhava OV, Krukov NO, Rachmanova VI, Orlovskaya DD. Ultrastructural damage of capillaries in the neocortex in schizophrenia. World J Biol Psychiatry. 2010;11:567–78.
7. Cai HQ, Catts VS, Webster MJ, Galletly C, Liu D, O'Donnell M, et al. Increased macrophages and changed brain endothelial cell gene expression in the frontal cortex of people with schizophrenia displaying inflammation. Mol Psychiatry. 2020;25:761–75.
8. Wilhelm I, Nyul-Tóth Á, Suciu M, Hermenean A, Krizbai IA. Heterogeneity of the blood–brain barrier. Tissue Barriers. 2016:e1143544.
9. Cirt C, Skrabinine S, Vietes-Prado A, Topilko T, Bertin P, Gerschenfeld G, et al. Mapping the Fine-Scale Organization and plasticity of the brain vasculature. Cell. 2019;200:780–90.e725.
10. Davson H, Matchett PA. The kinetics of penetration of the blood-aqueous barrier. J Physiol. 1953;122:11–32.
11. Hammarlund-Udenaes M, Friden M, Syvonen S, Gupta A. On the rate and extent of drug delivery to the brain. Pharm Res. 2008;25:1737–50.
12. Gupta A, Chatelain P, Massingham R, Jonsson EN, Hammarlund-Udenaes M. Brain distribution of cetirizine enantiomers: comparison of three different tissue-to-plasma partition coefficients: $K_{\text{p,fi}}$, $K_{\text{p,fi}}$, and $K_{\text{p,fi}}$. Drug Metab Dispos. 2006;34:318–23.
13. Hammarlund-Udenaes M, Paažlová LK, de Lange EC. Drug equilibration across the blood-brain barrier-pharmacokinetic considerations based on the microdialysis method. Pharm Res. 1997;14:128–34.
14. Gustafsson S, Eriksson J, Syvänen S, Eriksson O, Hammarlund-Udenaes M, Antoni G. Combined PET and microdialysis for in vivo estimation of drug blood-brain barrier transport and brain unbound concentrations. Neuroimage. 2017;155:177–86.
15. Kutuzov N, Flyvbjerg B, Lauritzen M. Contributions of the glycocalyx, endothelium, and extravascular compartment to the blood–brain barrier. Proc Natl Acad Sci. 2018;115:E9429.
16. Takasu T, Rapport SJ, Smith OR. An in situ brain perfusion technique to study cerebrovascular transport in the rat. Am J Physiol-Heart Circulatory Physiol. 1984;247:H484–H493.
17. Helms HC, Abbott NJ, Burek M, Cechelli R, Couraud P-O, Deli MA, et al. In vitro models of the blood-brain barrier: An overview of commonly used brain endothelial cell culture models and guidelines for their use. J Cereb Blood Flow Metab. 2016;36:862–90.
18. Bergmann S, Lawler SE, Qu Y, Fadzen CM, Wolfe JM, Regan MS, et al. Blood–brain barrier organoids for investigating the permeability of CNS therapeutics. Nat Protoc. 2018;13:2827–43.
relevance for the distribution in brain and CSF of selected BCRP and P-gp substrates. Mol Pharmaceutics. 2017;14:4346–47.
34. Uchida Y, Wakayama K, Ohtsuki S, Chiba M, Ohe T, Ishii Y, et al. Blood-brain barrier pharmacoproteomics-based reconstruction of the in vivo brain distribution of P-glycoprotein substrates in cynomolgus monkeys. J Pharm Exp Ther. 2014;350:578–88.
35. Kirch MS. An analysis of FDA-approved drugs for oncology. Drug Discov Today. 2014;19:1831–3.
36. De Lange ECM, vd Berg DJ, Bellanti F, Voskyl RA, Syvén S. P-glycoprotein protein expression versus functionality at the blood-brain barrier using immunohistochemistry, microdissection and mathematical modeling. Eur J Pharm Sci. 2018;124:61–70.
37. Doorduin J, de Vries EFJ, Dierckx RA, Klein HC. P-glycoprotein activity in the brain–barrier is affected by virus-induced neuroinflammation and anti-psychotic treatment. Neuropharmacology. 2014;85:58–53.
38. Bernstein H-G, Hildebrandt J, Dobrowolny H, Steiner J, Bogerts B, Pahnke J. Morphometric analysis of the cerebral expression of ATP-binding cassette transporter ABCB1 in chronic schizophrenia: Circumscribed deficits in the habenula. Schizophrenia Res. 2016;172:52–58.
39. Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, et al. The ARRIVE guidelines 2019: updated guidelines for reporting animal research. bioRxiv. 2019. https://doi.org/10.1101/703181.
40. Krzywinski M, Altman N. Power and sample size. Nat Methods. 2013;10:1139–40.
41. Paxinos G, Franklin KBJ. Paxinos and Franklin’s the mouse brain in stereotaxic coordinates. 4th edn. Amsterdam: Elsevier Academic Press; 2013.

ACKNOWLEDGEMENTS
We gratefully acknowledge the excellent assistance of Jessica Dunhall (Uppsala University, PKPD group) with neuroPK and brain-slice studies. We express our sincere gratitude to Dr. Markus Fridén (Uppsala University, PKPD group, and AstraZeneca, Sweden) for fruitful discussions and excellent feedback on the concept of mapping blood-brain uptake using MSL. This work was financially supported by the Swedish Research Council (Medicine and Health, grant 2018-03320, Natural and Engineering Science, grant 2018-05501), ARIADME, a European Community’s Seventh Framework Program (FP7 ITN, grant 607517), the Swedish Brain Foundation (grant FO2018-0292), the Science for Life Laboratory and Uppsala University (all to P.E.A.). IL was funded by Innovative Medicines Initiative Two Joint Undertaking projects IM2PACT and NeuroDeRisk (grants 807015 and 821528, respectively) and the Swedish Research Council (grant 2018-03310 to M.H.U.).

AUTHOR CONTRIBUTIONS
D.L.: investigation, formal analysis, methodology, validation, writing—original draft, writing—review and editing, and visualization. T.V.: methodology, investigation, formal analysis, writing—review and editing. A.N. and R.S.: methodology, writing—review and editing, visualization, and supervision. M.H.U.: conceptualization, methodology, resources, writing—review and editing. I.L.: conceptualization, methodology, formal analysis and validation, writing—review and editing, visualization, project administration, and supervision. P.E.A.: conceptualization, methodology, resources, validation, writing—review and editing, visualization, project administration, supervision, and funding acquisition as principal investigator.

COMPETING INTERESTS
The authors declare no competing interests.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41389-021-01267-y.
Correspondence and requests for materials should be addressed to Irena Loryan or Per E. Andrén.
Reprints and permission information is available at http://www.nature.com/reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
